Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-16 08:00:47 EDT

PhotosVideosAllPeople
LatestRanked
@pharmaphorum.bsky.socialOct 16, 2026, 10:55 AM

#Roche has claimed #US approval for IL-6 receptor antagonist #Enspryng in a second indication – #thyroideyedisease (TED) – that furthers its ambition to grow the drug into a blockbuster product.

pharmaphorum.com/news/fda-cle...

@midgardfinance.comOct 16, 2026, 7:00 AM

💉 #pharma #immunology

🇨🇭 $RO: FDA approved #Enspryng for thyroid eye disease, a home injection every four weeks, against eight IV infusions of 🇺🇸 $AMGN's #Tepezza.

Tepezza sold €495m in Q2, Enspryng €108m in all its uses. One of its two TED trials missed.

midgardfinance.com/companies/ROP.SW/

Line chart titled "Tepezza and Enspryng quarterly sales", worldwide sales per quarter in euros from Q1 2024 to Q2 2026, axis marked 0 to 600 million euros. The violet Tepezza line, Amgen's thyroid eye disease drug, moves between about €362m and €495m a quarter, from €390m to €495m. The light blue Enspryng line, Roche's, sits far below it and climbs slowly from €69m to €108m, about a fifth of Tepezza in the last quarter.